Our collective data suggest that ATRX loss provides a selective advantage to OS cells by reducing barriers to tumor initiation, increasing tumor growth rate, increasing migratory/invasive capacity, and enhancing survival in the metastatic niche. The gene discussed is ATRX; the disease is neoplasm.